July 21, 2022 02:52 PM EDTUpdated 04:05 PM

Advocates call on ViiV to lower price of long-acting HIV injectable

Nicole DeFeudis

Editor

More than 70 advocates — ranging from actors to CEOs — signed a letter to ViiV chief executive Deborah Waterhouse on Tuesday requesting a lower price for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Advocates call on ViiV to lower price of long-acting HIV injectable

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Maze files for first biotech IPO of 2025, following $115M funding boost

Ad­vo­cates call on Vi­iV to low­er price of long-act­ing HIV in­jectable

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Advocates call on ViiV to lower price of long-acting HIV injectable